Webinar: Sarepta Therapeutics – Data update from MOMENTUM study, SRP-5051
by: Parent Project Muscular Dystrophy
Sarepta Therapeutics recently joined PPMD for a community webinar: Data Update From the MOMENTUM Study of SRP-5051. Sarepta Therapeutics was invited to share data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in people living with Duchenne muscular dystrophy who are amenable to skipping exon 51.
by: Parent Project Muscular Dystrophy
